Valuation: Orion Oyj

Market Cap 11.48B 13.18B 10.84B 9.84B 18.44B 1,264B 18.5B 129B 50.09B 643B 49.48B 48.39B 2,069B P/E 2026 *
20.3x
P/E 2027 * 17.2x
Enterprise Value 11.39B 13.07B 10.75B 9.76B 18.29B 1,254B 18.36B 128B 49.7B 638B 49.09B 48.01B 2,053B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 4.69x
Free-Float
90.5%
Yield 2026 *
2.39%
Yield 2027 * 2.66%
1 week+4.09%
Current month+3.17%
1 month+3.04%
3 months+21.67%
6 months+16.29%
Current year+28.59%
1 week 78.5
Extreme 78.5
82.1
1 month 77.9
Extreme 77.9
82.1
Current year 62.3
Extreme 62.3
82.7
1 year 56.3
Extreme 56.3
82.7
3 years 32.5
Extreme 32.5
82.7
5 years 32.5
Extreme 32.5
82.7
10 years 24.75
Extreme 24.75
82.7
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+4.09% - - 13.16B
+0.04%+3.34%+53.32%+102.40% 1,028B
-0.09%+1.66%+53.24%+65.73% 651B
-0.02%+2.66%+18.65%+71.84% 466B
-1.22%+3.66%+34.59%+39.32% 346B
-0.79%+2.73%+17.73%+23.91% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+42.07% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+97.98% 186B
Average +0.03%+3.26%+25.25%+44.94% 400.19B
Weighted average by Cap. -0.04%+3.09%+34.84%+61.72%

Financials

2026 *2027 *
Net sales 2.1B 2.41B 1.98B 1.8B 3.37B 231B 3.38B 23.66B 9.15B 118B 9.04B 8.84B 378B 2.37B 2.72B 2.24B 2.03B 3.81B 261B 3.83B 26.78B 10.36B 133B 10.23B 10.01B 428B
Net income 566M 650M 534M 485M 909M 62.32B 912M 6.38B 2.47B 31.71B 2.44B 2.39B 102B 668M 767M 631M 573M 1.07B 73.55B 1.08B 7.53B 2.91B 37.42B 2.88B 2.82B 120B
Net Debt -89.76M -103M -84.74M -76.95M -144M -9.88B -145M -1.01B -392M -5.03B -387M -378M -16.18B -333M -382M -314M -285M -535M -36.66B -537M -3.76B -1.45B -18.66B -1.44B -1.4B -60.02B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change Volume
26-09-18 €81.40 0.00% 7,956
26-09-17 €81.40 +1.50% 6,090
26-09-16 €80.20 +1.39% 8,426
26-09-15 €79.10 -0.38% 1,334
26-09-14 €79.40 +1.53% 9,521
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
81.50EUR
Average target price
76.67EUR
Spread / Average Target
-5.93%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!